Mark Bloch

Summary

Publications

  1. ncbi Adherence to HIV treatment guidelines for comorbid disease assessment and initiation of antiretroviral therapy
    Mark Bloch
    Holdsworth House Medical Practice, Sydney, NSW, Australia
    J Acquir Immune Defic Syndr 59:478-88. 2012
  2. ncbi Triple-class HIV antiretroviral therapy failure in an Australian primary care setting
    Mark Bloch
    Holdsworth House Medical Practice, Darlinghurst, NSW, Australia
    Sex Health 7:17-24. 2010
  3. ncbi Adherence to treatment for recently acquired hepatitis C virus (HCV) infection among injecting drug users
    Jason Grebely
    National Centre in HIV Epidemiology and Clinical Research, University of New South Wales, Sydney, Australia
    J Hepatol 55:76-85. 2011
  4. ncbi Factors associated with uptake of treatment for recent hepatitis C virus infection in a predominantly injecting drug user cohort: The ATAHC Study
    J Grebely
    National Centre in HIV Epidemiology and Clinical Research, University of New South Wales, 376 Victoria Street, Darlinghurst, Sydney, NSW 2010, Australia
    Drug Alcohol Depend 107:244-9. 2010
  5. ncbi Predictors of limb fat gain in HIV positive patients following a change to tenofovir-emtricitabine or abacavir-lamivudine
    Allison Martin
    The Kirby Institute formerly the National Centre in HIV Epidemiology and Clinical Research, University of New South Wales, Sydney, New South Wales, Australia
    PLoS ONE 6:e26885. 2011
  6. ncbi Potential role for interleukin-28B genotype in treatment decision-making in recent hepatitis C virus infection
    Jason Grebely
    National Centre in HIV Epidemiology and Clinical Research NCHECR, University of New South Wales UNSW, Sydney, Australia
    Hepatology 52:1216-24. 2010
  7. ncbi Simplification of antiretroviral therapy with tenofovir-emtricitabine or abacavir-Lamivudine: a randomized, 96-week trial
    Allison Martin
    National Centre in HIV Epidemiology and Clinical Research UNSW, 5St Vincent s Centre for Applied Medical Research, Sydney, Australia
    Clin Infect Dis 49:1591-601. 2009
  8. ncbi A randomized study of pharmacokinetics, efficacy, and safety of 2 raltegravir plus atazanavir strategies in ART-treated adults
    Dianne Carey
    Kirby Institute University of New South Wales, Sydney, Australia
    J Acquir Immune Defic Syndr 60:143-9. 2012
  9. ncbi Effective treatment of injecting drug users with recently acquired hepatitis C virus infection
    Gregory J Dore
    National Centre in HIV Epidemiology and Clinical Research, University of New South Wales, Sydney, Australia
    Gastroenterology 138:123-35.e1-2. 2010
  10. ncbi Impact of treatment with raltegravir during primary or chronic HIV infection on RNA decay characteristics and the HIV viral reservoir
    Kersten K Koelsch
    The Kirby Institute, University of New South Wales, Sydney, Australia
    AIDS 25:2069-78. 2011

Collaborators

Detail Information

Publications15

  1. ncbi Adherence to HIV treatment guidelines for comorbid disease assessment and initiation of antiretroviral therapy
    Mark Bloch
    Holdsworth House Medical Practice, Sydney, NSW, Australia
    J Acquir Immune Defic Syndr 59:478-88. 2012
    ..There are limited data on adherence to HIV treatment guidelines. We assessed adherence to US Department of Health and Human Services guidelines with Australian Commentary for adults initiating antiretroviral therapy (ART)...
  2. ncbi Triple-class HIV antiretroviral therapy failure in an Australian primary care setting
    Mark Bloch
    Holdsworth House Medical Practice, Darlinghurst, NSW, Australia
    Sex Health 7:17-24. 2010
    ....
  3. ncbi Adherence to treatment for recently acquired hepatitis C virus (HCV) infection among injecting drug users
    Jason Grebely
    National Centre in HIV Epidemiology and Clinical Research, University of New South Wales, Sydney, Australia
    J Hepatol 55:76-85. 2011
    ..We assessed 80/80 adherence (≥80% of PEG-IFN doses, ≥80% treatment), on-treatment adherence, and treatment completion in a study of treatment of recent HCV infection (ATAHC)...
  4. ncbi Factors associated with uptake of treatment for recent hepatitis C virus infection in a predominantly injecting drug user cohort: The ATAHC Study
    J Grebely
    National Centre in HIV Epidemiology and Clinical Research, University of New South Wales, 376 Victoria Street, Darlinghurst, Sydney, NSW 2010, Australia
    Drug Alcohol Depend 107:244-9. 2010
    ..Decisions about whether to initiate treatment for recently acquired HCV were mainly driven by clinical factors, rather than factors related to sociodemographics or injecting behaviors...
  5. ncbi Predictors of limb fat gain in HIV positive patients following a change to tenofovir-emtricitabine or abacavir-lamivudine
    Allison Martin
    The Kirby Institute formerly the National Centre in HIV Epidemiology and Clinical Research, University of New South Wales, Sydney, New South Wales, Australia
    PLoS ONE 6:e26885. 2011
    ..We examined predictors of anthropometric outcomes over 96 weeks in HIV-infected, lipoatrophic adults receiving stable cART randomised to tenofovir-emtricitabine (TDF-FTC) or abacavir-lamivudine (ABC-3TC) fixed dose combinations...
  6. ncbi Potential role for interleukin-28B genotype in treatment decision-making in recent hepatitis C virus infection
    Jason Grebely
    National Centre in HIV Epidemiology and Clinical Research NCHECR, University of New South Wales UNSW, Sydney, Australia
    Hepatology 52:1216-24. 2010
    ..Early therapeutic intervention could be recommended for individuals with unfavorable IL28B genotypes...
  7. ncbi Simplification of antiretroviral therapy with tenofovir-emtricitabine or abacavir-Lamivudine: a randomized, 96-week trial
    Allison Martin
    National Centre in HIV Epidemiology and Clinical Research UNSW, 5St Vincent s Centre for Applied Medical Research, Sydney, Australia
    Clin Infect Dis 49:1591-601. 2009
    ..Which fixed-dose-combination tablet is more effective and safe is uncertain...
  8. ncbi A randomized study of pharmacokinetics, efficacy, and safety of 2 raltegravir plus atazanavir strategies in ART-treated adults
    Dianne Carey
    Kirby Institute University of New South Wales, Sydney, Australia
    J Acquir Immune Defic Syndr 60:143-9. 2012
    ..New antiretroviral drug classes provide opportunities to explore novel regimens...
  9. ncbi Effective treatment of injecting drug users with recently acquired hepatitis C virus infection
    Gregory J Dore
    National Centre in HIV Epidemiology and Clinical Research, University of New South Wales, Sydney, Australia
    Gastroenterology 138:123-35.e1-2. 2010
    ..We evaluated the efficacy of treatment of recent HCV infection in IDUs with acute and early chronic HCV...
  10. ncbi Impact of treatment with raltegravir during primary or chronic HIV infection on RNA decay characteristics and the HIV viral reservoir
    Kersten K Koelsch
    The Kirby Institute, University of New South Wales, Sydney, Australia
    AIDS 25:2069-78. 2011
    ..In most patients, rebound upon treatment cessation is prompt. We assessed whether early treatment with raltegravir can impact on the formation of the viral reservoir...
  11. ncbi Characteristics and treatment outcomes among HIV-infected individuals in the Australian Trial in Acute Hepatitis C
    G V Matthews
    National Centre in HIV Epidemiology and Clinical Research, University of New South Wales, Sydney, Australia
    Clin Infect Dis 48:650-8. 2009
    ..Enrollment is open to both human immunodeficiency virus (HIV)-infected and -uninfected individuals. The aim of this article was to evaluate characteristics and virological outcomes among HIV-infected individuals enrolled in ATAHC...
  12. ncbi Atazanavir trough plasma concentration monitoring in a cohort of HIV-1-positive individuals receiving highly active antiretroviral therapy
    Alan Winston
    National Centre in HIV Epidemiology and Clinical Research, University of New South Wales, Sydney, 2010, Australia
    J Antimicrob Chemother 56:380-7. 2005
    ..The aim of this study was to assess the clinical associations with plasma atazanavir concentrations in HIV-positive individuals...
  13. ncbi Predictors of bacterial pneumonia in Evaluation of Subcutaneous Interleukin-2 in a Randomized International Trial (ESPRIT)
    S L Pett
    National Centre in HIV Epidemiology and Clinical Research, University of New South Wales, Sydney, Australia
    HIV Med 12:219-27. 2011
    ..cART alone (control arm) in HIV-infected adults with CD4 counts ≥300cells/μL, offered the opportunity to explore associations between bacterial pneumonia and rIL-2, a cytokine that increases the risk of some bacterial infections...
  14. ncbi Poly-l-lactic acid for HIV-1 facial lipoatrophy: 48-week follow-up
    D Carey
    National Centre in HIV Epidemiology and Clinical Research, The University of New South Wales, Sydney, NSW, Australia
    HIV Med 10:163-72. 2009
    ..Poly-l-lactic acid (PLA) injections modestly increase objectively assessed facial thickness but not facial soft tissue volume (FSTV) over 24 weeks. The durability of this response has not been well defined objectively...
  15. ncbi 2-day versus 5-day famciclovir as treatment of recurrences of genital herpes: results of the FaST study
    Neil Bodsworth
    Taylor Square Private Clinic, Darlinghurst, NSW 2010, Australia
    Sex Health 5:219-25. 2008
    ..The brief period of viral replication in recurrent genital herpes lesions suggests shorter therapeutic regimens may be as effective as standard 5-day courses...